|
Market Closed -
Nasdaq
16:00:00 2026-09-03 EDT
|
5-day change | 1st Jan Change | ||
| 2.140 USD | 0.00% |
|
-0.47% | -38.15% |
| 08-24 | Grace Therapeutics Files for Resale of Up to 4.8 Million Shares | MT |
| 08-13 | Grace Therapeutics, Inc. Reports Impairment charges for the First Quarter Ended June 30, 2026 | CI |
Company Valuation: Grace Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 67.46 | 27.76 | 43.57 | 44.96 | 100 | 62.3 | - | - |
| Change | - | -58.85% | 56.94% | 3.19% | 122.45% | -37.7% | - | - |
| Enterprise Value (EV) | 67.46 | 27.76 | 43.57 | 44.96 | 100 | 62.3 | 62.3 | 62.3 |
| Change | - | -58.85% | 56.94% | 3.19% | 122.45% | -37.7% | 0% | 0% |
| P/E | -4.36x | -0.5x | -2.5x | -3.02x | -9.8x | -1.78x | -4.63x | 6.18x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | 0x | 0.1x | 0.2x | -0x | 0.1x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - | 9.11x | 1.01x |
| EV / Revenue | - | - | - | - | - | - | 9.11x | 1.01x |
| EV / EBITDA | - | - | - | -0x | -0x | -4.01x | -5.22x | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -3.87x | -3.68x | 3.23x |
| EV / FCF | - | - | -0x | -0x | -0x | -3.68x | -0.71x | -4.55x |
| FCF Yield | - | - | -38.9% | -45.6% | -12.5% | -27.2% | -141% | -22% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.094 | -7.529 | -1.851 | -1.085 | -0.6593 | -1.667 | -0.64 | 0.479 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | 6.841 | 61.57 |
| EBITDA 1 | - | - | - | -22.9 | -15.65 | -15.54 | -11.93 | - |
| EBIT 1 | -20.25 | -24.56 | -15.59 | -22.91 | -15.54 | -16.09 | -16.92 | 19.29 |
| Net income 1 | -12.76 | -55.88 | -17.63 | -13.14 | -10.93 | -34.73 | -16.92 | 19.29 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 9.139 | 3.733 | 4.635 | 3.277 | 6.463 | 2.962 | 2.962 | 2.962 |
| Nbr of stocks (in thousands) | 7,381 | 7,435 | 9,399 | 13,718 | 15,474 | 21,036 | - | - |
| Announcement Date | 6/21/22 | 6/23/23 | 6/21/24 | 6/23/25 | 6/18/26 | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.78x | - | - | - | 45.02M | |
| 20.44x | 7.17x | 14.49x | 1.43% | 68.87B | |
| 37.07x | 9.67x | 29.5x | 0.04% | 65.29B | |
| -77.51x | 14.96x | -72.15x | -.--% | 27.65B | |
| 29.76x | 6.36x | 16.52x | -.--% | 25.77B | |
| -15.9x | 6.16x | -7.74x | -.--% | 26.08B | |
| 27.51x | 5.14x | 17.12x | -.--% | 20.14B | |
| 49.22x | 18.16x | 36.83x | 0.31% | 17.03B | |
| 1298.7x | 37.56x | 819.65x | -.--% | 15.03B | |
| 18.08x | 5.39x | 12.58x | -.--% | 14.5B | |
| Average | 138.56x | 12.29x | 96.31x | 0.2% | 28.04B | |
| Weighted average by Cap. | 82.76x | 10.41x | 52.16x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- GRCE Stock
- Valuation Grace Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
